Evommune EVMN Increase (decrease) in other current liabilities
Increase (decrease) in other current liabilities at other companies
Other financials
Where this comes from
Reported directly by Evommune in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherCurrentLiabilities.
The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Evommune 's increase (decrease) in other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Evommune 's increase (decrease) in other current liabilities?
- Evommune (EVMN) reported increase (decrease) in other current liabilities of -$11.15K in Q1 2026.
- How has Evommune 's increase (decrease) in other current liabilities changed year-over-year?
- Evommune 's increase (decrease) in other current liabilities decreased by 57.8% year-over-year, from -$7.07K to -$11.15K.
- What does increase (decrease) in other current liabilities mean?
- Captures the net change in miscellaneous short-term obligations not classified as accounts payable or accrued expenses. This includes items such as deferred revenue or other short-term accruals that impact the company's immediate liquidity position. Tracking this helps identify shifts in non-trade short-term financial commitments.